Table 3 The similarities and differences between tumor-derived Igs and B-cell-derived Igs.
From: Current insights into the expression and functions of tumor-derived immunoglobulins
| Â | Characteristics | B lymphocyte-derived Igs | Tumor-derived Igs | References |
|---|---|---|---|---|
Similarities | Molecular structure | + | + | [16] |
| Â | Natural antibody activity | + | + | [35] |
Differences | IgG gene diversity | Unlimited diversity | Limited diversity | |
| Â | Glycosylation patterns | One N-glycosylation at N297 position and terminal NeuAc | O-linked and N-linked glycans, terminal NeuAc and NeuGc | |
|  | Expression regulatory mechanisms | Transcription factors include Oct-1, Oct-2, NF-κB, B-cell Oct-binding factor-1 and others | Transcription factors include Oct-1 but not Oct-2 | |
| Â | Immunoactivity | Normal | Low | |
| Â | Biological functions | Phagocytosis and neutralize toxins (IgG); mucosal immunity and neonatal immunity (IgA); protection against invasion of blood by microbial pathogens. (IgM); initiation of immune responses (IgD). Antiparasitic immunity and antihypersensitivity (IgE) | Tumor proliferation, metastasis, immune escape, and other biological behavior of tumors |
